U0126-EtOH [1173097-76-1]
Katalog-Nummer HY-12031-100mg
Size : 100mg
Marke : MedChemExpress
U0126 (U0126-EtOH) est un inhibiteur puissant de MEK1 et MEK2, non compétitif et compétitif, avec IC50s de 72 nM et 58 nM, respectivement. U0126 est un autophagie et un inhibiteur de mitophagie.
U0126 (U0126-EtOH) ist ein potenter, nicht-ATP-kompetitiver und selektiver MEK1 und MEK2-Inhibitor mit IC50s von 72 nM bzw. 58 nM. U0126 ist ein autophagy- und mitophagy-Inhibitor.
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
U0126-EtOH Chemische Struktur
CAS. Nr. : 1173097-76-1
This product is a controlled substance and not for sale in your territory.
Based on 387 publication(s) in Google Scholar
Other Forms of U0126-EtOH:
- U0126 In-stock
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Mar 7;115489. [Abstract]
- U0126 (20 uM; pretreat for 2 h) rescues the loss of UHRF1/DNMT1 expression and the increase of E-Cadherin expression that induced by Lenvatinib in Huh7 cells.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2023 Feb 17;111891. [Abstract]
- U0126 (10 uM; pre-treate for 1 h) attenuates IL-1-induced upregulation of COX-2 expression in KGN cells.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Res. 2019 Sep 1;79(17):4466-4479. [Abstract]
- Western blot and IHC analyses for p-ERK1/2 in lung tissues after vehicle or U0126 treatment.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673. [Abstract]
- Western analysis of α-SMA, Collagen I and E-cadherin protein expression in the treatment of U0126 with different concentrations.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673. [Abstract]
- Western analysis of Vimentin, E-cadherin and Snail1 protein expression with or without the treatment of U0126.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Jan;120(1):321-331. [Abstract]
- U0126 enhances the negative effect of Fsk-IBMX on the development of glioma stem cells (GSCs).
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374. [Abstract]
- MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Blood. 2018 Jul 12;132(2):210-222. [Abstract]
- Phosphorylation of p-ERK1/2 and p-Akt in MKs pretreated with 0.5 μM NVP-ADW742, 10 μM U0126 or 20 μM LY294002 followed by rhIGF-1 treatment for 15 minutes.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomaterials. 2018 Sep;178:95-108. [Abstract]
- U0126 effectively inhibits the phosphorylation of ERK, leading to the inhibition of IL-10 production.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 28;430:201-214. [Abstract]
- Inhibition of ERK suppresses N-cadherin expression. CD146WT or CD146KO MEFs are stimulated with or without TGF-β1 (10 ng/mL) for 24 h in the presence or absence of U0126 (2 μM). The expression and activation of ERK and the expression of E-cadherin and N-cadherin is assessed by immunoblotting.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]
- Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]
- Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Jun 15;15(1):184. [Abstract]
- Representative immunoblots of total lysates from BV2 cells treated with MPP+or/and U0126 (10 μM), SP600125 (SP, 10 μM) and SB203580 (SB, 10 μM) using the antibodies against DICER.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 3;9(10):1015. [Abstract]
- Representative western blot images are showing the LC3, and the phosphorylated and total protein expression of Akt and ERK1/2 after treatment with H2O2 in the presence and absence of MK2206 (5 μM) and U0126 (25 μM).
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269. [Abstract]
- WB is used to detect the effect of EGF treatment on the expression of YAP with the inhibitors of EGFR or its downsream members.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2018 Mar 15;42:152-163. [Abstract]
- Cells are pretreated with SP600125 (20 μM), SB203580 (20 μM) or U0126 (20 μM) in presence or absence of KLA, then incubated with LPS (1 μg/mL) for certain time. Cell lysates are subjected to western blot.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Feb 19;100:417-425. [Abstract]
- HaCaT cells are pre-incubated with Compound C (CC) (10 μM) and U0126 (10 μM), pharmacological inhibitors of AMPKα, ERK, respectively, for 1 h before treatment with DA8 and DA14 (DAs).
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302. [Abstract]
- As for both 0 g and 3 g groups, the p-p38&p38 is downregulated by inhibitors SB203580, SP600125, and U0126.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302. [Abstract]
- The protein level of MMP-9 is downregulated by inhibitors SB203580, SP600125, and U0126.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302. [Abstract]
- As for both 0 g and 3 g groups, the p-JNK1&JNK1 is downregulated by inhibitors SB203580, SP600125, and U0126.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302. [Abstract]
- The protein levels of IL-1β and TNF-α are sharply downregulated by the addition of inhibitors SB203580, SP600125, and U0126.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302. [Abstract]
- As for both 0 g and 3 g groups, the p-ERK1/2/ERK1/2 is notably reduced by inhibitors SB203580, SP600125, and U0126.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Front Immunol. 2018 Dec 7;9:2854. [Abstract]
- Neutrophils are pretreated with inhibitor of p38 MAPK (SB203580) and ERK1/2 (U0126), and the cells are then incubated with either SS2 ZY05719 or PMA for 3 h. Immunofluorescence is performed.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Reprod Biol Endocrinol. 2018 May 31;16(1):55. [Abstract]
- Western blot analysis of claudin 5, occludin and ZO-1 in TM4 cells, cells are treated with 100 nM Leptin or pre-treated with different inhibitors following a 100 nM Leptin treatment.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Sep 19. [Abstract]
- Western blot shows the expression of p-ERK and MMP13 with the treatment of U0126 and CCL17.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2018 Jun;17(6):7595-7602. [Abstract]
- Representative images show the expression levels of α SMA, calponin and osteopontin (OPN) protein.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2018;50(4):1522-1534. [Abstract]
- Western analysis of effect of U0126 on Nell-1-induced changes in p-ERK, Runx2, OPG and Col-I protein expression in MC3T3-E1 preosteoblasts on Ti surfaces.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Feb 16;393:22-32. [Abstract]
- Effects of p38 MAPK inhibitor (SB203580), ERK inhibitor (U0126), JNK inhibitor (SP600125), caspase inhibitor (Z-VAD-FMK) and NAC on SGC-7901 and MGC-803 treated with DOX/VCPA combination treatment. VCPA pretreatment strategy is the same as above. SB203580 (20 μM), U0126 (10 μM), SP600125 (20 μM), Z-VAD-FMK (10 μM) and NAC (5 mM) are treated 2 h before DOX (2 μg/mL) added into the culture, respectively. MAPK pathway protein levels are determined.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2017 Nov;112:49-59. [Abstract]
- Cells are pre-treated with ERK (U1026) and p38 (SB203580) inhibitors, followed by GL-V9 treatment for 24 h. Western blot is performed to analyze NAG-1 expression.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Jan 16;32:48-58. [Abstract]
- Western blotting showing the hepaCAMexpression and the phosphorylation level of STAT3, ERK and AKT in cells treated with IL-6 (20 ng/mL) for 24 h with or without the pretreatment of two respective inhibitors, Stattic (10 μM) and U0126 (5 μM).
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2017 Apr 3;16(7):714-722. [Abstract]
- Proliferation of OPCs by AST induced calcium signaling and phosphorylated ERK1/2. p-ERK levels decreased after Cx47 siRNA treatment and U0126-mediated ERK1/2 inhibition. The results of Western blotting show that U0126 causes a marked decrease in ERK1/2 phosphorylation
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 30;8(47):82027-82036. [Abstract]
- U0126 and MEK162 block ERK activation (p-ERK1/2) in CZ415-treated U2OS cells.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017;2017:7426458. [Abstract]
- Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 16;8(20):33807-33826. [Abstract]
- U0126 inhibits ERK1/2 activation in the kidney of hyperuricemic rats. Rat model of HN is established by feeding with adenine and potassium oxonate daily. In some rats, U0126 are simultaneously administrated intraperitoneally. After 28 days, the kidneys are taken for immunoblot analysis of p-ERK1/2, ERK1/2 or GAPDH.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017;2017:6175841. [Abstract]
- Involvements of MAPK signaling pathway in CPS-induced apoptosis in ALI cultures of sheep bronchial epithelial cells. Cells are pretreated with U0126 (an ERK1/2 inhibitor, 10 μM) for 1 h, followed by exposure to CPS (100 ng/mL) or MO (MOI = 30) for 48 h. Cell lysates are subjected to Western blotting analysis using indicated antibodies.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: ACS Chem Neurosci. 2015 Jan 21;6(1):130-7. [Abstract]
- U0126 protects PC12 cells against H2O2-induced cell death. Western blot of ERK phosphorylation demonstrates that the MEK inhibitors U0126, GSK1120212 and Pimasertib are effective in blocking ERK phosphorylation under complete media, while U0124 results in slight ERK inhibition compared to DMSO control. Serum starvation results in lack of ERK phosphorylation in all conditions.
-
U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Mol Cell Cardiol. 2015 Dec;89(Pt B):268-79. [Abstract]
- Dose response of MAPK and Akt inhibitors on cardiac fibroblast-derived exosomes (Exo)-induced activation of MAPKs and Akt. Neonatal rat cardiomyocytes are treated with or without Exo (50 μg/mL), U0126, SP600125, MK-2206, and SB023580 for 20 min and subjected to Western blot analysis. The results are from 4 separate experiments.